Auxesis Pharma's pharmaceutical portfolio includes approved products and drug candidates within local pain management, dermatology and veterinary medicine.
Our pharmaceutical products are developed for topical and targeted treatment directly where pain, irritation or skin conditions occur.
A pharmaceutical development track for the medical treatment of seborrhoeic keratoses.
Derivexa™ is a topical drug candidate being developed for the local treatment and removal of seborrhoeic keratoses.
Before
TreatmentA topical drug candidate for local pain treatment without an intended central opioid effect.
Opirexa™ is a pharmaceutical development project based on loperamide and is being developed for targeted treatment of local skin- and wound-related pain.
Topical pain treatment for animals.
CoxyPet is being developed for the local treatment of pain, irritation and swelling in animals.
We develop science-based products with the aim of improving quality of life for people and animals — directly where the problem occurs.
All projects are currently under development. Safety, efficacy, formulation and regulatory pathways are evaluated within each respective development programme.